Scinovex
articleTop 1% cited

Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody Fragment

Archives of Ophthalmology · 2002 · Vol. 120(3) · pp. 338–338
Magdalena G. Krzystolik

Abstract

This study provides the nonclinical proof of principle for ongoing clinical studies of intravitreally injected rhuFab VEGF in patients with neovascular age-related macular degeneration.

Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal and Optic ConditionsMedicineChoroidal neovascularizationOphthalmologyVascular endothelial growth factorFluorescein angiographyNeovascularizationVEGF receptorsAngiogenesisMacular degenerationVisual acuity

MeSH terms

AnimalsAntibodies, MonoclonalDisease Models, AnimalFluorescein AngiographyImmunoglobulin FragmentsInjectionsLymphokinesMacaca fascicularisRecombinant Fusion ProteinsSafetyUveitis, AnteriorVitreous BodyEndothelial Growth FactorsLaser CoagulationChoroidal Neovascularization
Citations
588
FWCI
36.94
field-weighted impact
References
13
Percentile
100%
vs. same field & year
Citations per year
Cited by
Macrophage Depletion Inhibits Experimental Choroidal Neovascularization
Investigative Ophthalmology & Visual Science · 2003 · 513 citations
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Investigative Ophthalmology & Visual Science · 2005 · 502 citations
The biology of VEGF and its receptors
Nature Medicine · 2003 · 9,519 citations
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Nature Reviews Drug Discovery · 2006 · 1,556 citations
Current Concepts in the Pathogenesis of Age-Related Macular Degeneration
Archives of Ophthalmology · 2004 · 1,001 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.